Biolegend, 566704, Biotinylated Recombinant Human SLAMF6-Fc Chimera (carrier-free), 25μg

SLAMF6, also known as NTB-A, is one of the members in the CD2/CD150 subfamily. SLAMF6 is a type I transmembrane glycoprotein and it is expressed on NK cells, T cells and B cells in humans. It is also found on macrophages, dendritic cells and granulocytes in mice. SLAMF6 is a self-ligand receptor. The homophilic interaction with SLAMF6-expressing cells and engagement of SLAMF6 by antibody-mediated cross-linking or recombinants trigger NK cell cytotoxicity, cytokine production and cell proliferation.  In addition, the homophilic interaction of SLAMF6 is involved in CD28 independent T cell co-stimulation, triggering Th1 cytokine production, and regulation of B cell tolerance. After stimulation, phosphorylated SLAMF6 associates with SAP/ SH2D1A and EAT-2/ SH2D1B adaptor proteins. Functional assays demonstrated that SAP is dispensable for SLAMF6-mediated cytotoxicity, but SLAMF6-mediated IFNγ production is impaired in the absence of SAP. In mice, SLAMF6, also called Ly108, plays an important role in CD4 + T cell responses and innate immunity to bacteria and parasites. In SLAMF6-deficient mice, CD4 + T cells and innate responses are defective. The SLAM family of receptors has been implicated in the pathophysiology of autoimmunity. SLAMF6 may censor self-reactive B cells as a potential regulator of tolerance checkpoints, safeguarding against autoimmunity. SLAMF6 is strongly linked to lupus susceptibility in mice and human patients. Therefore, SLAMF6 serves as a regulator of both innate and adaptive immune responses. Engagement of SLAMF6 along with CD3/TCR stimulation induces IL-17 production.
25μg
Source: Human SLAMF6 (NTB-A), amino acid (Leu28-Lys225) (Accession: # Q96DU3.3), with a linker (GS), a C-terminal human IgG (Pro100-Lys330) an Avi-tag, was expressed in CHO cells. Human SLAMF6-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass: The 446 amino acid recombinant protein has a predicted molecular mass of approximately 50.23 kD. The DTT-reduced and non-reduced protein migrates at approximately 62 – 80 kD and 115 – 140 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Leu.
Purity: > 95%, as determined by Coomassie stained SDS-PAGE.
Formulation: 0.22 µm filtered protein solution is in PBS.
Endotoxin Level: Less than 0.1 EU per µg cytokine as determined by the LAL method.
Concentration: 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool
Storage & Handling: Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity: When recombinant human SLAMF6-Fc (Cat. No. 784606) is immobilized at 1 µ/mL, biotinylated recombinant human SLAMF6 binds in a dose-dependent manner with ED50 of 1 – 6 µg/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
Application: Bioassay
Application Notes: BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Structure: CD2 subfamily
Distribution: Expressed in resting and activated NK cells, T cells, B cells; plasma membrane
Function: CD28 independent T cell co-stimulation, induction of NK cell cytotoxicity, regulation of B cell tolerance; plays an important role in CD4+ T cell responses, innate immunity to bacteria and parasites, and NK cell function
Interaction: SAP/ SH2D1A, EAT-2/ SH2D1B, Src kinase
Ligand/Receptor: SLAMF6 (self-ligand)
Bioactivity: Biotinylated recombinant human SLAMF6-Fc binds to immobilized recombinant human SLAMF6-Fc in a dose-dependent manner using a binding assay.
Cell Type: B cells, Dendritic cells, Granulocytes, Macrophages, NK cells, T cells, Thymocytes
Biology Area: Adaptive Immunity, Cell Biology, Immunology, Innate Immunity
Molecular Family: CD Molecules, Immune Checkpoint Receptors, Soluble Receptors
Antigen References: Bottino C, et al. 2001. J ExpMed. 194:235. Eissmann P, et al. 2006. J Immunol. 177:3170-7. Chatterjee M, et al. 2012. J Immunol. 188:1206-12. Howie D, et al. 2005. J Immunol. 174:5931-5. Valdez PA, et al. 2004. J Biol Chem. 279:18662-9. Kumar KR, et al. 2006. Science. 312:1665-9. Flaig RM, et al. 2004. J. Immunol. 172:6524-7. Wang N, et al. 2016. Clin Immunol. 173:19-26.
Gene ID: 114836
UniProt: View information about SLAMF6 on UniProt.org
Regulatory Status: RUO
Other Names: SLAMF6, SLAM family member 6, Activating NK receptor, NK-T-Bantigen, NTB-A